A case of dupilumab-induced psoriasis-like eruption treated with baricitinib.

Autor: Kinoshita Y; Department of Dermatology Osaka Metropolitan University Graduate School of Medicine Osaka Japan., Imanishi H; Department of Dermatology Osaka Metropolitan University Graduate School of Medicine Osaka Japan., Oshimo T; Department of Dermatology Osaka Metropolitan University Graduate School of Medicine Osaka Japan., Tsuruta D; Department of Dermatology Osaka Metropolitan University Graduate School of Medicine Osaka Japan.
Jazyk: angličtina
Zdroj: Skin health and disease [Skin Health Dis] 2024 Jan 16; Vol. 4 (2), pp. e338. Date of Electronic Publication: 2024 Jan 16 (Print Publication: 2024).
DOI: 10.1002/ski2.338
Abstrakt: Dupilumab is a humanized monoclonal antibody against the interleukin (IL)-4 receptor alpha chain that inhibits IL-4 and IL-13 signalling. It is one of the systemic treatments for patients with moderate-to-severe atopic dermatitis (AD), which provides favourable safety and efficacy. We report a case of psoriasis-like eruption induced by dupilumab as an adverse effect in a patient with AD, immediately remitted after switching to baricitinib, which inhibits JAK1/2. Moreover, the atopic skin lesion also simultaneously went into remission upon baricitinib treatment. Baricitinib could be a favourable option for patients with AD who develop dupilumab-induced psoriasis-like eruption.
Competing Interests: The authors declare no conflicts of interest.
(© 2024 The Authors. Skin Health and Disease published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.)
Databáze: MEDLINE
Externí odkaz: